APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cardiovascular Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cardiovascular Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchCardiovascular Disease Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiovascular Disease Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cardiovascular Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiovascular Disease Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiovascular Disease Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cardiovascular Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cardiovascular Disease Drugs include Takeda Pharmaceutical, Sanofi, Johnson＆Johnson, Novartis, Merck, Roche, Pfizer, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cardiovascular Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cardiovascular Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cardiovascular Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cardiovascular Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cardiovascular Disease Drugs Segment by Company

Takeda Pharmaceutical

Sanofi

Johnson＆Johnson

Novartis

Merck

Roche

Pfizer

Bayer

AstraZeneca

United Therapeutics Corporation

Daiichi Sankyo Company Limited

Boehringer Ingelheim

Astellas Pharma

Actelion Pharmaceuticals

Cardiovascular Disease Drugs Segment by Type

Lotrel

Zebeta

Coumadin

Sectral

Heparin

Lopressor

Norvasc

Toprol XL

Others

Cardiovascular Disease Drugs Segment by Application

Stroke

Dyslipidemia

Thrombosis

Peripheral Artery Disease

Asischemic Heart Disease

Coronary Artery Diseases

Atherosclerosis

Others

Cardiovascular Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cardiovascular Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cardiovascular Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cardiovascular Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cardiovascular Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cardiovascular Disease Drugs Industry Trends Table 2. Cardiovascular Disease Drugs Industry Drivers Table 3. Cardiovascular Disease Drugs Industry Opportunities and Challenges Table 4. Cardiovascular Disease Drugs Industry Restraints Table 5. Global Cardiovascular Disease Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cardiovascular Disease Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cardiovascular Disease Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Cardiovascular Disease Drugs Sales Market Share by Manufacturers Table 9. Global Cardiovascular Disease Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cardiovascular Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cardiovascular Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cardiovascular Disease Drugs Manufacturers, Product Type & Application Table 13. Global Cardiovascular Disease Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cardiovascular Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lotrel Table 17. Major Manufacturers of Zebeta Table 18. Major Manufacturers of Coumadin Table 19. Major Manufacturers of Sectral Table 20. Major Manufacturers of Heparin Table 21. Major Manufacturers of Lopressor Table 22. Major Manufacturers of Norvasc Table 23. Major Manufacturers of Toprol XL Table 24. Major Manufacturers of Others Table 25. Global Cardiovascular Disease Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Cardiovascular Disease Drugs Sales by Type (2021-2026) & (W Units) Table 27. Global Cardiovascular Disease Drugs Sales by Type (2027-2032) & (W Units) Table 28. Global Cardiovascular Disease Drugs Sales Market Share by Type (2021-2026) Table 29. Global Cardiovascular Disease Drugs Sales Market Share by Type (2027-2032) Table 30. Global Cardiovascular Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 31. Global Cardiovascular Disease Drugs Revenue by Type (2021-2026) & (W Units) Table 32. Global Cardiovascular Disease Drugs Revenue by Type (2027-2032) & (W Units) Table 33. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2021-2026) Table 34. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2027-2032) Table 35. Major Manufacturers of Stroke Table 36. Major Manufacturers of Dyslipidemia Table 37. Major Manufacturers of Thrombosis Table 38. Major Manufacturers of Peripheral Artery Disease Table 39. Major Manufacturers of Asischemic Heart Disease Table 40. Major Manufacturers of Coronary Artery Diseases Table 41. Major Manufacturers of Atherosclerosis Table 42. Major Manufacturers of Others Table 43. Global Cardiovascular Disease Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 44. Global Cardiovascular Disease Drugs Sales by Application (2021-2026) & (W Units) Table 45. Global Cardiovascular Disease Drugs Sales by Application (2027-2032) & (W Units) Table 46. Global Cardiovascular Disease Drugs Sales Market Share by Application (2021-2026) Table 47. Global Cardiovascular Disease Drugs Sales Market Share by Application (2027-2032) Table 48. Global Cardiovascular Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 49. Global Cardiovascular Disease Drugs Revenue by Application (2021-2026) & (W Units) Table 50. Global Cardiovascular Disease Drugs Revenue by Application (2027-2032) & (W Units) Table 51. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2021-2026) Table 52. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2027-2032) Table 53. Global Cardiovascular Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Cardiovascular Disease Drugs Sales by Region (2021-2026) & (W Units) Table 55. Global Cardiovascular Disease Drugs Sales Market Share by Region (2021-2026) Table 56. Global Cardiovascular Disease Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 57. Global Cardiovascular Disease Drugs Sales Forecasted Market Share by Region (2027-2032) Table 58. North America Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. North America Cardiovascular Disease Drugs Sales by Country (2021-2026) & (W Units) Table 60. North America Cardiovascular Disease Drugs Sales by Country (2027-2032) & (W Units) Table 61. Europe Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. Europe Cardiovascular Disease Drugs Sales by Country (2021-2026) & (W Units) Table 63. Europe Cardiovascular Disease Drugs Sales by Country (2027-2032) & (W Units) Table 64. Asia Pacific Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 65. Asia Pacific Cardiovascular Disease Drugs Sales by Country (2021-2026) & (W Units) Table 66. Asia Pacific Cardiovascular Disease Drugs Sales by Country (2027-2032) & (W Units) Table 67. South America, Middle East and Africa Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 68. South America, Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2021-2026) & (W Units) Table 69. South America, Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2027-2032) & (W Units) Table 70. Global Cardiovascular Disease Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 71. Global Cardiovascular Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 72. Global Cardiovascular Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 73. Global Cardiovascular Disease Drugs Revenue Market Share by Region (2021-2026) Table 74. Global Cardiovascular Disease Drugs Revenue Market Share by Region (2027-2032) Table 75. Takeda Pharmaceutical Company Information Table 76. Takeda Pharmaceutical Business Overview Table 77. Takeda Pharmaceutical Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio Table 79. Takeda Pharmaceutical Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sanofi Cardiovascular Disease Drugs Product Portfolio Table 84. Sanofi Recent Development Table 85. Johnson＆Johnson Company Information Table 86. Johnson＆Johnson Business Overview Table 87. Johnson＆Johnson Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Johnson＆Johnson Cardiovascular Disease Drugs Product Portfolio Table 89. Johnson＆Johnson Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Novartis Cardiovascular Disease Drugs Product Portfolio Table 94. Novartis Recent Development Table 95. Merck Company Information Table 96. Merck Business Overview Table 97. Merck Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Merck Cardiovascular Disease Drugs Product Portfolio Table 99. Merck Recent Development Table 100. Roche Company Information Table 101. Roche Business Overview Table 102. Roche Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Roche Cardiovascular Disease Drugs Product Portfolio Table 104. Roche Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Pfizer Cardiovascular Disease Drugs Product Portfolio Table 109. Pfizer Recent Development Table 110. Bayer Company Information Table 111. Bayer Business Overview Table 112. Bayer Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bayer Cardiovascular Disease Drugs Product Portfolio Table 114. Bayer Recent Development Table 115. AstraZeneca Company Information Table 116. AstraZeneca Business Overview Table 117. AstraZeneca Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. AstraZeneca Cardiovascular Disease Drugs Product Portfolio Table 119. AstraZeneca Recent Development Table 120. United Therapeutics Corporation Company Information Table 121. United Therapeutics Corporation Business Overview Table 122. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio Table 124. United Therapeutics Corporation Recent Development Table 125. Daiichi Sankyo Company Limited Company Information Table 126. Daiichi Sankyo Company Limited Business Overview Table 127. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio Table 129. Daiichi Sankyo Company Limited Recent Development Table 130. Boehringer Ingelheim Company Information Table 131. Boehringer Ingelheim Business Overview Table 132. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio Table 134. Boehringer Ingelheim Recent Development Table 135. Astellas Pharma Company Information Table 136. Astellas Pharma Business Overview Table 137. Astellas Pharma Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Astellas Pharma Cardiovascular Disease Drugs Product Portfolio Table 139. Astellas Pharma Recent Development Table 140. Actelion Pharmaceuticals Company Information Table 141. Actelion Pharmaceuticals Business Overview Table 142. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio Table 144. Actelion Pharmaceuticals Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Cardiovascular Disease Drugs Distributors List Table 148. Cardiovascular Disease Drugs Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Cardiovascular Disease Drugs Product Image Figure 2. Global Cardiovascular Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cardiovascular Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cardiovascular Disease Drugs Sales (2021-2032) & (W Units) Figure 5. Global Cardiovascular Disease Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cardiovascular Disease Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lotrel Image Figure 9. Zebeta Image Figure 10. Coumadin Image Figure 11. Sectral Image Figure 12. Heparin Image Figure 13. Lopressor Image Figure 14. Norvasc Image Figure 15. Toprol XL Image Figure 16. Others Image Figure 17. Global Cardiovascular Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Cardiovascular Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cardiovascular Disease Drugs Sales Market Share by Type (2021-2032) Figure 20. Global Cardiovascular Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Cardiovascular Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2021-2032) Figure 23. Stroke Image Figure 24. Dyslipidemia Image Figure 25. Thrombosis Image Figure 26. Peripheral Artery Disease Image Figure 27. Asischemic Heart Disease Image Figure 28. Coronary Artery Diseases Image Figure 29. Atherosclerosis Image Figure 30. Others Image Figure 31. Global Cardiovascular Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 32. Global Cardiovascular Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 33. Global Cardiovascular Disease Drugs Sales Market Share by Application (2021-2032) Figure 34. Global Cardiovascular Disease Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Cardiovascular Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 36. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2021-2032) Figure 37. North America Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. North America Cardiovascular Disease Drugs Sales Market Share by Country (2021-2032) Figure 39. U.S. Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Canada Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Mexico Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Europe Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Europe Cardiovascular Disease Drugs Sales Market Share by Country (2021-2032) Figure 44. Germany Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. France Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. U.K. Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Italy Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Netherlands Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Asia Pacific Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Asia Pacific Cardiovascular Disease Drugs Sales Market Share by Country (2021-2032) Figure 51. China Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Japan Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South Korea Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Southeast Asia Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. India Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Australia Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. South America, Middle East and Africa Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. South America, Middle East and Africa Cardiovascular Disease Drugs Sales Market Share by Country (2021-2032) Figure 59. Brazil Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 60. South Africa Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Saudi Arabia Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 62. Turkey Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 63. Argentina Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 64. UAE Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 65. Egypt Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 66. Chile Cardiovascular Disease Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 67. Global Cardiovascular Disease Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Global Cardiovascular Disease Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 69. North America Cardiovascular Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 70. North America Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Europe Cardiovascular Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 72. Europe Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Asia-Pacific Cardiovascular Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 74. Asia-Pacific Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 75. South America, Middle East and Africa Cardiovascular Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 76. South America, Middle East and Africa Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 77. Cardiovascular Disease Drugs Value Chain Figure 78. Manufacturing Cost Structure Figure 79. Cardiovascular Disease Drugs Production Mode & Process Figure 80. Direct Comparison with Distribution Share Figure 81. Distributors Profiles Figure 82. Years Considered Figure 83. Research Process Figure 84. Key Executives Interviewed

Scope & coverage.

Types
  • Lotrel
  • Zebeta
  • Coumadin
  • Sectral
  • Heparin
  • Lopressor
  • Norvasc
  • Toprol XL
  • Others
Applications
  • Stroke
  • Dyslipidemia
  • Thrombosis
  • Peripheral Artery Disease
  • Asischemic Heart Disease
  • Coronary Artery Diseases
  • Atherosclerosis
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi
  • Johnson＆Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • Bayer
  • AstraZeneca
  • United Therapeutics Corporation
  • Daiichi Sankyo Company Limited
  • Boehringer Ingelheim
  • Astellas Pharma
  • Actelion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cardiovascular Disease Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cardiovascular Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cardiovascular Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cardiovascular Disease Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cardiovascular Disease Drugs Market Dynamics
  1. 2.1 Cardiovascular Disease Drugs Industry Trends
  2. 2.2 Cardiovascular Disease Drugs Industry Drivers
  3. 2.3 Cardiovascular Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Cardiovascular Disease Drugs Industry Restraints
3 Cardiovascular Disease Drugs Market by Manufacturers
  1. 3.1 Global Cardiovascular Disease Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cardiovascular Disease Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cardiovascular Disease Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cardiovascular Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cardiovascular Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cardiovascular Disease Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Cardiovascular Disease Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cardiovascular Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cardiovascular Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cardiovascular Disease Drugs Tier 1, Tier 2, and Tier 3
4 Cardiovascular Disease Drugs Market by Type
  1. 4.1 Cardiovascular Disease Drugs Type Introduction
  2. 4.1.1 Lotrel
  3. 4.1.2 Zebeta
  4. 4.1.3 Coumadin
  5. 4.1.4 Sectral
  6. 4.1.5 Heparin
  7. 4.1.6 Lopressor
  8. 4.1.7 Norvasc
  9. 4.1.8 Toprol XL
  10. 4.1.9 Others
  11. 4.2 Global Cardiovascular Disease Drugs Sales by Type
  12. 4.2.1 Global Cardiovascular Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Cardiovascular Disease Drugs Sales by Type (2021-2032)
  14. 4.2.3 Global Cardiovascular Disease Drugs Sales Market Share by Type (2021-2032)
  15. 4.3 Global Cardiovascular Disease Drugs Revenue by Type
  16. 4.3.1 Global Cardiovascular Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Cardiovascular Disease Drugs Revenue by Type (2021-2032)
  18. 4.3.3 Global Cardiovascular Disease Drugs Revenue Market Share by Type (2021-2032)
5 Cardiovascular Disease Drugs Market by Application
  1. 5.1 Cardiovascular Disease Drugs Application Introduction
  2. 5.1.1 Stroke
  3. 5.1.2 Dyslipidemia
  4. 5.1.3 Thrombosis
  5. 5.1.4 Peripheral Artery Disease
  6. 5.1.5 Asischemic Heart Disease
  7. 5.1.6 Coronary Artery Diseases
  8. 5.1.7 Atherosclerosis
  9. 5.1.8 Others
  10. 5.2 Global Cardiovascular Disease Drugs Sales by Application
  11. 5.2.1 Global Cardiovascular Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
  12. 5.2.2 Global Cardiovascular Disease Drugs Sales by Application (2021-2032)
  13. 5.2.3 Global Cardiovascular Disease Drugs Sales Market Share by Application (2021-2032)
  14. 5.3 Global Cardiovascular Disease Drugs Revenue by Application
  15. 5.3.1 Global Cardiovascular Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  16. 5.3.2 Global Cardiovascular Disease Drugs Revenue by Application (2021-2032)
  17. 5.3.3 Global Cardiovascular Disease Drugs Revenue Market Share by Application (2021-2032)
6 Global Cardiovascular Disease Drugs Sales by Region
  1. 6.1 Global Cardiovascular Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cardiovascular Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cardiovascular Disease Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Cardiovascular Disease Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cardiovascular Disease Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cardiovascular Disease Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cardiovascular Disease Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cardiovascular Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cardiovascular Disease Drugs Revenue by Region
  1. 7.1 Global Cardiovascular Disease Drugs Revenue by Region
  2. 7.1.1 Global Cardiovascular Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cardiovascular Disease Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Cardiovascular Disease Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Cardiovascular Disease Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cardiovascular Disease Drugs Revenue (2021-2032)
  8. 7.2.2 North America Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cardiovascular Disease Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cardiovascular Disease Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cardiovascular Disease Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cardiovascular Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Cardiovascular Disease Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson＆Johnson
  14. 8.3.1 Johnson＆Johnson Company Information
  15. 8.3.2 Johnson＆Johnson Business Overview
  16. 8.3.3 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson＆Johnson Cardiovascular Disease Drugs Product Portfolio
  18. 8.3.5 Johnson＆Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Cardiovascular Disease Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Cardiovascular Disease Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Cardiovascular Disease Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Cardiovascular Disease Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Cardiovascular Disease Drugs Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Cardiovascular Disease Drugs Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 United Therapeutics Corporation
  56. 8.10.1 United Therapeutics Corporation Company Information
  57. 8.10.2 United Therapeutics Corporation Business Overview
  58. 8.10.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio
  60. 8.10.5 United Therapeutics Corporation Recent Developments
  61. 8.11 Daiichi Sankyo Company Limited
  62. 8.11.1 Daiichi Sankyo Company Limited Company Information
  63. 8.11.2 Daiichi Sankyo Company Limited Business Overview
  64. 8.11.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio
  66. 8.11.5 Daiichi Sankyo Company Limited Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Astellas Pharma
  74. 8.13.1 Astellas Pharma Company Information
  75. 8.13.2 Astellas Pharma Business Overview
  76. 8.13.3 Astellas Pharma Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Cardiovascular Disease Drugs Product Portfolio
  78. 8.13.5 Astellas Pharma Recent Developments
  79. 8.14 Actelion Pharmaceuticals
  80. 8.14.1 Actelion Pharmaceuticals Company Information
  81. 8.14.2 Actelion Pharmaceuticals Business Overview
  82. 8.14.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio
  84. 8.14.5 Actelion Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cardiovascular Disease Drugs Value Chain Analysis
  2. 9.1.1 Cardiovascular Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cardiovascular Disease Drugs Production Mode & Process
  6. 9.2 Cardiovascular Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cardiovascular Disease Drugs Distributors
  9. 9.2.3 Cardiovascular Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst